Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates

The study investigates the use of biodegradable dendritic polyglycerol sulfates (dPGS-PCL) as a carrier for the topical delivery of tofacitinib (TFB) to treat inflammatory skin diseases like alopecia areata. The dPGS-PCL@TFB system showed better skin penetration and reduced activation of STAT3 and STAT5 in an ex vivo human skin model compared to free TFB, although it did not significantly inhibit IL-6 and IL-8 release. The findings suggest that dPGS-PCL@TFB could be a promising dermal drug delivery system, but further studies are needed to confirm its long-term efficacy and safety.